Valuation: Verastem, Inc.

Market Cap 519M 451M 422M 386M 729M 49.47B 738M 4.94B 1.94B 24.72B 1.95B 1.91B 82.27B P/E 2026 *
-3.77x
P/E 2027 * -5.32x
Enterprise Value 354M 307M 288M 263M 497M 33.75B 504M 3.37B 1.32B 16.86B 1.33B 1.3B 56.13B EV / Sales 2026 *
3.28x
EV / Sales 2027 * 1.72x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -
1 day+6.68%
1 week+6.47%
Current month+6.47%
1 month+27.32%
3 months+9.10%
6 months-7.14%
Current year-20.01%
1 week 5.58
Extreme 5.58
7.1
1 month 4.67
Extreme 4.6705
7.1
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Chief Executive Officer

-1,302 0.0017%
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+6.60%+6.47%+9.88%-39.58% 519M
+8.49%+23.38%+65.44%+104.90% 62.92B
+1.25%+2.44%+32.55%+72.63% 54.32B
+2.14%+2.97%-16.24%-5.31% 22.91B
-3.13%+30.55%+17.77%+488.59% 28.73B
+10.83%+21.32%+45.03%+2.02% 21.65B
+6.50%+7.56%+38.20%-21.33% 17.76B
-3.88%+20.98%+201.07%+350.94% 16.47B
+6.20%+12.16%+28.51%+629.05% 15.48B
+1.89%+0.28%+42.23%+162.62% 13.12B
Average +3.72%+6.37%+46.44%+174.45% 25.39B
Weighted average by Cap. +3.85%+9.92%+47.23%+164.47%

Financials

2026 *2027 *
Net sales 108M 93.71M 87.75M 80.27M 152M 10.29B 154M 1.03B 403M 5.14B 405M 397M 17.11B 180M 156M 146M 133M 252M 17.11B 255M 1.71B 670M 8.55B 674M 660M 28.45B
Net income -154M -134M -125M -114M -216M -14.67B -219M -1.46B -575M -7.33B -578M -566M -24.4B -130M -113M -106M -96.66M -182M -12.39B -185M -1.24B -485M -6.19B -488M -478M -20.6B
Net Debt -165M -143M -134M -123M -232M -15.72B -235M -1.57B -616M -7.85B -620M -606M -26.14B -210M -182M -170M -156M -294M -19.97B -298M -1.99B -782M -9.98B -787M -770M -33.2B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
08/08/26 USD 6.175 +4.48% 1,932,253
06/08/26 USD 5.910 +0.68% 2,189,459
05/08/26 USD 5.870 +1.03% 1,554,979
04/08/26 USD 5.810 +2.11% 1,791,796
03/08/26 USD 5.690 -1.90% 1,288,075
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.910USD
Average target price
14.88USD
Spread / Average Target
+151.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock